Lee's Pharmaceutical Holdings Limited (0950.HK)
HKD 1.3
(6.56%)
HKD 1.3
(6.56%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 590.99 Million HKD | -14.9% |
| 2022 | 694.48 Million HKD | -21.91% |
| 2021 | 889.38 Million HKD | 28.68% |
| 2020 | 691.18 Million HKD | 13.07% |
| 2019 | 611.3 Million HKD | 11.21% |
| 2018 | 549.66 Million HKD | 26.56% |
| 2017 | 434.3 Million HKD | 23.78% |
| 2016 | 350.86 Million HKD | -14.26% |
| 2015 | 409.23 Million HKD | -6.52% |
| 2014 | 437.79 Million HKD | 32.39% |
| 2013 | 330.69 Million HKD | 30.74% |
| 2012 | 252.93 Million HKD | 26.55% |
| 2011 | 199.87 Million HKD | 83.86% |
| 2010 | 108.71 Million HKD | 52.72% |
| 2009 | 71.18 Million HKD | 23.17% |
| 2008 | 57.79 Million HKD | 53.94% |
| 2007 | 37.54 Million HKD | 24.02% |
| 2006 | 30.27 Million HKD | 14.11% |
| 2005 | 26.52 Million HKD | 13.46% |
| 2004 | 23.38 Million HKD | 23.68% |
| 2003 | 18.9 Million HKD | 40.6% |
| 2002 | 13.44 Million HKD | 26.66% |
| 2001 | 10.61 Million HKD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q4 | 128.9 Million HKD | 0.0% |
| 2023 Q2 | 126.49 Million HKD | 0.0% |
| 2023 Q1 | 126.49 Million HKD | 18.32% |
| 2023 FY | 590.99 Million HKD | -14.9% |
| 2023 Q3 | 128.9 Million HKD | 1.9% |
| 2022 Q4 | 106.9 Million HKD | -46.76% |
| 2022 Q1 | 190.62 Million HKD | -36.47% |
| 2022 Q2 | 200.34 Million HKD | 5.1% |
| 2022 Q3 | 200.79 Million HKD | 0.23% |
| 2022 FY | 694.48 Million HKD | -21.91% |
| 2021 Q2 | 216.07 Million HKD | 25.74% |
| 2021 Q4 | 300.06 Million HKD | 23.12% |
| 2021 FY | 889.38 Million HKD | 28.68% |
| 2021 Q3 | 243.72 Million HKD | 12.79% |
| 2021 Q1 | 171.84 Million HKD | -13.47% |
| 2020 FY | 691.18 Million HKD | 13.07% |
| 2020 Q1 | 134.74 Million HKD | 155.77% |
| 2020 Q2 | 164.11 Million HKD | 21.8% |
| 2020 Q3 | 195.79 Million HKD | 19.31% |
| 2020 Q4 | 198.6 Million HKD | 1.43% |
| 2019 FY | 611.3 Million HKD | 11.21% |
| 2019 Q3 | 163.35 Million HKD | 3.3% |
| 2019 Q4 | 52.68 Million HKD | -67.75% |
| 2019 Q1 | 127.17 Million HKD | -36.79% |
| 2019 Q2 | 158.13 Million HKD | 24.34% |
| 2018 Q4 | 201.19 Million HKD | 70.27% |
| 2018 Q2 | 102.05 Million HKD | -23.56% |
| 2018 Q1 | 133.51 Million HKD | 11.44% |
| 2018 FY | 549.66 Million HKD | 26.56% |
| 2018 Q3 | 118.16 Million HKD | 15.78% |
| 2017 Q2 | 104.76 Million HKD | 2.83% |
| 2017 Q1 | 101.87 Million HKD | 3.35% |
| 2017 FY | 434.3 Million HKD | 23.78% |
| 2017 Q3 | 107.98 Million HKD | 3.07% |
| 2017 Q4 | 119.8 Million HKD | 10.95% |
| 2016 Q4 | 98.57 Million HKD | 31.22% |
| 2016 Q3 | 75.11 Million HKD | -11.03% |
| 2016 Q1 | 104.93 Million HKD | 33.68% |
| 2016 Q2 | 84.43 Million HKD | -19.54% |
| 2016 FY | 350.86 Million HKD | -14.26% |
| 2015 FY | 409.23 Million HKD | -6.52% |
| 2015 Q3 | 92.83 Million HKD | -21.25% |
| 2015 Q2 | 117.89 Million HKD | -1.76% |
| 2015 Q1 | 120 Million HKD | 9.44% |
| 2015 Q4 | 78.49 Million HKD | -15.44% |
| 2014 Q2 | 111.57 Million HKD | 11.17% |
| 2014 Q3 | 116.2 Million HKD | 4.15% |
| 2014 Q4 | 109.65 Million HKD | -5.64% |
| 2014 FY | 437.79 Million HKD | 32.39% |
| 2014 Q1 | 100.36 Million HKD | 8.65% |
| 2013 Q2 | 83.47 Million HKD | 18.35% |
| 2013 Q3 | 84.31 Million HKD | 1.0% |
| 2013 Q4 | 92.37 Million HKD | 9.56% |
| 2013 FY | 330.69 Million HKD | 30.74% |
| 2013 Q1 | 70.53 Million HKD | 8.24% |
| 2012 FY | 252.93 Million HKD | 26.55% |
| 2012 Q3 | 62.87 Million HKD | -8.96% |
| 2012 Q1 | 54.17 Million HKD | 1.23% |
| 2012 Q2 | 69.06 Million HKD | 27.48% |
| 2012 Q4 | 65.16 Million HKD | 3.64% |
| 2011 Q1 | 34.98 Million HKD | 0.0% |
| 2011 Q4 | 53.52 Million HKD | 0.22% |
| 2011 FY | 199.87 Million HKD | 83.86% |
| 2011 Q2 | 48.35 Million HKD | 38.22% |
| 2011 Q3 | 53.4 Million HKD | 10.45% |
| 2010 FY | 108.71 Million HKD | 52.72% |
| 2010 Q2 | 23.99 Million HKD | 0.0% |
| 2009 Q2 | 18.08 Million HKD | 0.0% |
| 2009 FY | 71.18 Million HKD | 23.17% |
| 2008 FY | 57.79 Million HKD | 53.94% |
| 2007 FY | 37.54 Million HKD | 24.02% |
| 2006 FY | 30.27 Million HKD | 14.11% |
| 2005 FY | 26.52 Million HKD | 13.46% |
| 2004 FY | 23.38 Million HKD | 23.68% |
| 2003 FY | 18.9 Million HKD | 40.6% |
| 2002 FY | 13.44 Million HKD | 26.66% |
| 2001 FY | 10.61 Million HKD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -2319.718% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 84.692% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -1563.501% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -66.978% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -3355.689% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 51.911% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | -17.385% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -172.813% |
| SSY Group Limited | 1.98 Billion HKD | 70.163% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -260.634% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -105.67% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 97.987% |